000126774 001__ 126774 000126774 005__ 20241125101139.0 000126774 0247_ $$2doi$$a10.3390/biomedicines11071964 000126774 0248_ $$2sideral$$a134174 000126774 037__ $$aART-2023-134174 000126774 041__ $$aeng 000126774 100__ $$aGonzález-Flores, David 000126774 245__ $$aMelatonin as a Coadjuvant in the Treatment of Patients with Fibromyalgia 000126774 260__ $$c2023 000126774 5060_ $$aAccess copy available to the general public$$fUnrestricted 000126774 5203_ $$aFibromyalgia syndrome (FMS) is a chronic widespread pain syndrome that is accompanied by fatigue, sleep disturbances, anxiety, depression, lack of concentration, and neurocognitive impairment. As the currently available drugs are not completely successful against these symptoms and frequently have several side effects, many scientists have taken on the task of looking for nonpharmacological remedies. Many of the FMS-related symptoms have been suggested to be associated with an altered pattern of endogenous melatonin. Melatonin is involved in the regulation of several physiological processes, including circadian rhythms, pain, mood, and oxidative as well as immunomodulatory balance. Preliminary clinical studies have propounded that the administration of different doses of melatonin to patients with FMS can reduce pain levels and ameliorate mood and sleep disturbances. Moreover, the total antioxidant capacity, 6-sulfatoxymelatonin and urinary cortisol levels, and other biological parameters improve after the ingestion of melatonin. Recent investigations have proposed a pathophysiological relationship between mitochondrial dysfunction, oxidative stress, and FMS by looking at certain proteins involved in mitochondrial homeostasis according to the etiopathogenesis of this syndrome. These improvements exert positive effects on the quality of life of FMS patients, suggesting that the use of melatonin as a coadjuvant may be a successful strategy for the management of this syndrome. 000126774 536__ $$9info:eu-repo/grantAgreement/ES/DGA/B56-23D 000126774 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/ 000126774 590__ $$a3.9$$b2023 000126774 592__ $$a0.962$$b2023 000126774 591__ $$aPHARMACOLOGY & PHARMACY$$b85 / 354 = 0.24$$c2023$$dQ1$$eT1 000126774 593__ $$aMedicine (miscellaneous)$$c2023$$dQ1 000126774 591__ $$aBIOCHEMISTRY & MOLECULAR BIOLOGY$$b106 / 313 = 0.339$$c2023$$dQ2$$eT2 000126774 593__ $$aBiochemistry, Genetics and Molecular Biology (miscellaneous)$$c2023$$dQ1 000126774 591__ $$aMEDICINE, RESEARCH & EXPERIMENTAL$$b65 / 189 = 0.344$$c2023$$dQ2$$eT2 000126774 594__ $$a5.2$$b2023 000126774 655_4 $$ainfo:eu-repo/semantics/review$$vinfo:eu-repo/semantics/publishedVersion 000126774 700__ $$0(orcid)0000-0002-2455-680X$$aLópez-Pingarrón, Laura$$uUniversidad de Zaragoza 000126774 700__ $$aCastaño, María Yolanda 000126774 700__ $$aGómez, María Ángeles 000126774 700__ $$aRodríguez, Ana B 000126774 700__ $$0(orcid)0000-0001-9507-6478$$aGarcía, Joaquín J$$uUniversidad de Zaragoza 000126774 700__ $$aGarrido, María 000126774 7102_ $$11012$$2410$$aUniversidad de Zaragoza$$bDpto. Farmac.Fisiol.y Med.L.F.$$cÁrea Fisiología 000126774 773__ $$g11, 7 (2023), 1964 [18 pp.]$$tBiomedicines$$x2227-9059 000126774 8564_ $$s630808$$uhttps://zaguan.unizar.es/record/126774/files/texto_completo.pdf$$yVersión publicada 000126774 8564_ $$s2720464$$uhttps://zaguan.unizar.es/record/126774/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada 000126774 909CO $$ooai:zaguan.unizar.es:126774$$particulos$$pdriver 000126774 951__ $$a2024-11-22-12:02:02 000126774 980__ $$aARTICLE